| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-501 |
| filingDate |
2011-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2013-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EA-201270818-A1 |
| titleOfInvention |
6- (1-METHYL-1H-PYRAZOL-4-IL) -3- (2-METHYL-2H-INDAZOL-5-ILTIO) - [1,2,4] TRIAZOLE- [43-b] Pyridazine as an inhibitor c-MET |
| abstract |
The invention relates to a c-Met inhibitor (described herein) or a pharmaceutically acceptable salt thereof suitable for treating cancer mediated by c-Met receptor activity. |
| priorityDate |
2010-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |